Thursday, November 10, 2011
Putting a bias into antipsychotics. A team from The University of North Carolina at Chapel Hill and Duke University has
designed a class of antipsychotic compounds called b-arrestin-biased ligands that could have a better
therapeutic index than existing drugs to treat schizophrenia and other
antipsychotic drug Abilify as a synthetic scaffold, the researchers designed a
biased agonist that bound the dopamine D2 receptor [a] and activated downstream
signaling through the b-arrestin
pathway [b] without agonizing G protein-mediated pathways [c]. In
mice, the compound showed antipsychotic effects without triggering neurological
Abilify aripiprazole is marketed by Bristol-Myers Squibb Co.
and Otsuka Pharmaceutical Co. Ltd.
to treat depression, bipolar disorder and schizophrenia.